Patents by Inventor Tomoji MASHIMO

Tomoji MASHIMO has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240141310
    Abstract: The present inventors have found that by cultivating insect cells, into which the Cas3 gene has been introduced, at relatively low temperatures, it is possible to efficiently express recombinant Cas3 proteins with maintained activity, and by purifying the soluble fractions of these cells, it is possible to collect active forms of the recombinant Cas3 proteins in high purity and high yield.
    Type: Application
    Filed: February 25, 2022
    Publication date: May 2, 2024
    Applicants: C4U Corporation, The University of Tokyo, RIKEN
    Inventors: Tomoji MASHIMO, Kazuto YOSHIMI, Kohei TAKESHITA, Masaki YAMAMOTO, Satomi SHIBUMURA
  • Patent number: 11970706
    Abstract: Provided is a nonhuman animal model that is obtained by modifying a gene encoding thioredoxin and useful as a disease model of aging, kidney diseases, cardiovascular diseases, hypertension, aortic dissection, chronic obstructive lung disease, age-dependent epilepsy, abnormality of lipid metabolism, anemia, osteoporosis, abnormal immunity, etc. These variety of phenotypes are caused by the fact that a modification of a gene encoding thioredoxin induces hypofunction of thioredoxin expressed in multiple organs throughout the body. The gene encoding thioredoxin is a gene selected from among TXN, TRX, TRX1, RRDX, Txn1, Txn, Trx1 and ADF.
    Type: Grant
    Filed: December 6, 2018
    Date of Patent: April 30, 2024
    Assignees: HAMAMATSU PHOTONICS K.K.
    Inventors: Iori Ohmori, Mamoru Ouchida, Tomoji Mashimo
  • Publication number: 20240124898
    Abstract: A CRISPR-Cas3 system was successfully established in a eukaryotic cell.
    Type: Application
    Filed: September 14, 2023
    Publication date: April 18, 2024
    Applicant: OSAKA UNIVERSITY
    Inventors: Tomoji MASHIMO, Junji TAKEDA, Hiroyuki MORISAKA, Kazuto YOSHIMI
  • Publication number: 20240117381
    Abstract: A CRISPR-Cas3 system was successfully established in a eukaryotic cell.
    Type: Application
    Filed: September 14, 2023
    Publication date: April 11, 2024
    Applicant: OSAKA UNIVERSITY
    Inventors: Tomoji MASHIMO, Junji TAKEDA, Hiroyuki MORISAKA, Kazuto YOSHIMI
  • Patent number: 11807869
    Abstract: A CRISPR-Cas3 system was successfully established in a eukaryotic cell.
    Type: Grant
    Filed: June 8, 2018
    Date of Patent: November 7, 2023
    Assignee: OSAKA UNIVERSITY
    Inventors: Tomoji Mashimo, Junji Takeda, Hiroyuki Morisaka, Kazuto Yoshimi
  • Publication number: 20230099483
    Abstract: It has been found that by mixing a single-stranded probe DNA whose cleavage can be detected in a reaction system containing a CRISPR-Cas3 system and a sample from which to detect a target DNA, it is possible to detect the target DNA in the sample by using, as indication, a signal generated by the cleavage of the single-stranded probe DNA.
    Type: Application
    Filed: January 25, 2021
    Publication date: March 30, 2023
    Applicants: C4U CORPORATION, OSAKA UNIVERSITY
    Inventors: Tomoji MASHIMO, Kazuto YOSHIMI, Satomi SHIBUMURA
  • Patent number: 11530388
    Abstract: Methods are disclosed herein for producing human hepatocytes from human induced pluripotent stem cells. Also provided are transgenic rats for the expansion of human hepatocytes, such as those produced using the methods disclosed herein.
    Type: Grant
    Filed: February 13, 2018
    Date of Patent: December 20, 2022
    Assignee: University of Pittsburgh—Of the Commonwealth System of Higher Education
    Inventors: Alejandro Soto-Gutierrez, Tomoji Mashimo, Alexandra Sylvie Collin de l'Hortet, Eduardo Cervantes Alvarez, Jorge Guzman Lepe, Kan Handa, Kazuki Takeishi, Yang Wang, Branimir Popovic
  • Publication number: 20220186263
    Abstract: The present inventors have found that the use of a site-specific nuclease system which includes a combination of a molecule that simultaneously targets and cleaves one homology arm sequence of the donor DNA and the genomic sequence corresponding to the homology arm sequence, and a molecule that targets and cleaves the genomic region in the vicinity of the cleavage site by that molecule causes repair between genomic DNA and donor DNA through both non-homologous end joining and homologous recombination, making it possible to produce cells and organisms with knocked-in long donor sequences with high efficiency and accuracy.
    Type: Application
    Filed: April 3, 2020
    Publication date: June 16, 2022
    Applicant: OSAKA UNIVERSITY
    Inventors: Tomoji MASHIMO, Kazuto YOSHIMI, Yoshihiro UNO, Yuko KOTANI, Yoshiki MIYASAKA, Yuichiro OKA, Makoto SATO
  • Publication number: 20220017888
    Abstract: A production method of genomic DNA in which a deletion of more than 100 bases of nucleotides is introduced into a target region of the genomic DNA, the method includes a contact step of bringing a type I CRISPR associated complex for anti-viral defense (type I Cascade complex), CRISPR RNA (crRNA), and Cas3 protein into contact with the genomic DNA.
    Type: Application
    Filed: December 11, 2019
    Publication date: January 20, 2022
    Inventors: Akitsu HOTTA, Yuya OKUZAKI, Huaigeng XU, Peter David GEE, Yuto KITA, Tomoji MASHIMO, Kazuto YOSHIMI
  • Publication number: 20210171978
    Abstract: Provided is a nonhuman animal model that is obtained by modifying a gene encoding thioredoxin and useful as a disease model of aging, kidney diseases, cardiovascular diseases, hypertension, aortic dissection, chronic obstructive lung disease, age-dependent epilepsy, abnormality of lipid metabolism, anemia, osteoporosis, abnormal immunity, etc. These variety of phenotypes are caused by the fact that a modification of a gene encoding thioredoxin induces hypofunction of thioredoxin expressed in multiple organs throughout the body. The gene encoding thioredoxin is a gene selected from among TXN, TRX, TRX1, RRDX, Txn1, Txn, Trx1 and ADF.
    Type: Application
    Filed: December 6, 2018
    Publication date: June 10, 2021
    Applicant: HAMAMATSU PHOTONICS K.K.
    Inventors: Iori OHMORI, Mamoru OUCHIDA, Tomoji MASHIMO
  • Patent number: 10633674
    Abstract: An object is to develop a technology enabling utilization, by only an extremely simple technique, of a technology which is widely applicable to mammals without requiring the utilization of an ES cell, and which involves modifying a certain gene by targeting a certain sequence on a genome (genome editing technology based on ZFN or the like). Provided is a technology for efficiently modifying an arbitrary target gene of a mammal, by immersing a pronuclear stage mammalian zygote with an intact zona pellucida into a solution containing a pair of molecules of mRNA having a certain sequence, and performing electroporation treatment through application of multiple square-wave pulses in three steps with the total electric energy of a first electric pulse adjusted within a predetermined range.
    Type: Grant
    Filed: May 27, 2014
    Date of Patent: April 28, 2020
    Assignee: NEPA GENE CO., LTD.
    Inventors: Takehito Kaneko, Tomoji Mashimo, Yasuhiko Hayakawa, Kiyoshi Hayakawa
  • Publication number: 20200102580
    Abstract: A CRISPR-Cas3 system was successfully established in a eukaryotic cell.
    Type: Application
    Filed: June 8, 2018
    Publication date: April 2, 2020
    Applicant: OSAKA UNIVERSITY
    Inventors: Tomoji MASHIMO, Junji TAKEDA, Hirouki MORISAKA, Kazuto YOSHIMI
  • Publication number: 20200029538
    Abstract: A method for producing a genome edited cell or a non-human organism, comprising the step of introducing (a) an artificial nuclease system which cleaves both ends of a genome editing target region, and (b) a nucleic acid sequence formed by arranging a 5?-side homology arm sequence, a donor DNA sequence, and a 3?-side homology arm sequence in this order from a 5?-side, the 5?-side homology arm sequence being a homologous sequence of one nucleic acid sequence outside the genome editing target region, and the 3?-side homology arm sequence being a homologous sequence of the other nucleic acid sequence outside the genome editing target region, into a cell or a non-human organism.
    Type: Application
    Filed: November 24, 2017
    Publication date: January 30, 2020
    Applicant: OSAKA UNIVERSITY
    Inventors: Tomoji MASHIMO, Yoshiki MIYASAKA
  • Publication number: 20190382792
    Abstract: An object is to develop a technology enabling utilization, by only an extremely simple technique, of a technology which is widely applicable to mammals without requiring the utilization of an ES cell, and which involves modifying a certain gene by targeting a certain sequence on a genome (genome editing technology based on ZFN or the like). Provided is a technology for efficiently modifying an arbitrary target gene of a mammal, by immersing a pronuclear stage mammalian zygote with an intact zona pellucida into a solution containing a pair of molecules of mRNA having a certain sequence, and performing electroporation treatment through application of multiple square-wave pulses in three steps with the total electric energy of a first electric pulse adjusted within a predetermined range.
    Type: Application
    Filed: August 7, 2019
    Publication date: December 19, 2019
    Applicant: NEPA GENE CO., LTD.
    Inventors: Takehito Kaneko, Tomoji Mashimo, Yasuhiko Hayakawa, Kiyoshi Hayakawa
  • Publication number: 20190376029
    Abstract: Methods are disclosed herein for producing human hepatocytes from human induced pluripotent stem cells. Also provided are transgenic rats for the expansion of human hepatocytes, such as those produced using the methods disclosed herein.
    Type: Application
    Filed: February 13, 2018
    Publication date: December 12, 2019
    Applicant: University of Pittsburgh - Of the Commonwealth System of Higher Education
    Inventors: Alejandro Soto-Gutierrez, Tomoji Mashimo, Alexandra Sylvie Collin de l'Hortet, Eduardo Cervantes Alvarez, Jorge Guzman Lepe, Kan Handa, Kazuki Takeishi, Yang Wang, Branimir Popovic
  • Patent number: 10362771
    Abstract: This invention provides a method for knock-in of a donor DNA into the genome of a cell, comprising introducing at least one artificial nuclease system capable of cleaving target sequence(s) of the cell genome, the donor DNA, and two single-stranded oligonucleotides (ssODNs) into the cell, the artificial nuclease system cleaving the target sequence(s) on the cell genome, the two ssODNs each complementary to one of the ends generated by the target sequence cleavage in the cell genome and to one of the introduction ends of the donor DNA, the donor DNA being knocked-in at the cleavage site via the two ssODNs.
    Type: Grant
    Filed: November 17, 2015
    Date of Patent: July 30, 2019
    Assignee: KYOTO UNIVERSITY
    Inventors: Tomoji Mashimo, Kazuto Yoshimi, Takehito Kaneko
  • Publication number: 20170251647
    Abstract: This invention provides a method for knock-in of a donor DNA into the genome of a cell, comprising introducing at least one artificial nuclease system capable of cleaving target sequence(s) of the cell genome, the donor DNA, and two single-stranded oligonucleotides (ssODNs) into the cell, the artificial nuclease system cleaving the target sequence(s) on the cell genome, the two ssODNs each complementary to one of the ends generated by the target sequence cleavage in the cell genome and to one of the introduction ends of the donor DNA, the donor DNA being knocked-in at the cleavage site via the two ssODNs.
    Type: Application
    Filed: November 17, 2015
    Publication date: September 7, 2017
    Applicant: KYOTO UNIVERSITY
    Inventors: Tomoji MASHIMO, Kazuto YOSHIMI, Takehito KANEKO
  • Publication number: 20160215297
    Abstract: An object is to develop a technology enabling utilization, by only an extremely simple technique, of a technology which is widely applicable to mammals without requiring the utilization of an ES cell, and which involves modifying a certain gene by targeting a certain sequence on a genome (genome editing technology based on ZFN or the like). Provided is a technology for efficiently modifying an arbitrary target gene of a mammal, by immersing a pronuclear stage mammalian zygote with an intact zona pellucida into a solution containing a pair of molecules of mRNA having a certain sequence, and performing electroporation treatment through application of multiple square-wave pulses in three steps with the total electric energy of a first electric pulse adjusted within a predetermined range.
    Type: Application
    Filed: May 27, 2014
    Publication date: July 28, 2016
    Applicant: NEPA GENE CO., LTD.
    Inventors: Takehito KANEKO, Tomoji MASHIMO, Yasuhiko HAYAKAWA, Kiyoshi HAYAKAWA